CN109172756B - A Chinese medicinal composition for treating hepatopathy - Google Patents

A Chinese medicinal composition for treating hepatopathy Download PDF

Info

Publication number
CN109172756B
CN109172756B CN201811327689.3A CN201811327689A CN109172756B CN 109172756 B CN109172756 B CN 109172756B CN 201811327689 A CN201811327689 A CN 201811327689A CN 109172756 B CN109172756 B CN 109172756B
Authority
CN
China
Prior art keywords
traditional chinese
chinese medicine
liver
medicine composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811327689.3A
Other languages
Chinese (zh)
Other versions
CN109172756A (en
Inventor
舒积成
黄慧莲
彭财英
刘建群
杨明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi University of Traditional Chinese Medicine
Original Assignee
Jiangxi University of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi University of Traditional Chinese Medicine filed Critical Jiangxi University of Traditional Chinese Medicine
Priority to CN201811327689.3A priority Critical patent/CN109172756B/en
Publication of CN109172756A publication Critical patent/CN109172756A/en
Application granted granted Critical
Publication of CN109172756B publication Critical patent/CN109172756B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a traditional Chinese medicine composition for treating liver diseases, which comprises the following specific formula: lalang grass rhizome, Damnacanthus indicus, Acanthopanax gracilistylus and Lespedeza bicolor. The traditional Chinese medicine composition has the advantages of quick response, good curative effect, high cure rate, difficult relapse and no toxic or side effect on various liver diseases such as acute and chronic hepatitis B, hepatitis A, hepatitis C, liver cirrhosis, hepatic ascites, alcoholic liver disease and the like.

Description

A Chinese medicinal composition for treating hepatopathy
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating liver diseases.
Background
Chronic hepatitis refers to necrosis and inflammation of the liver caused by different causes, the course of which lasts for more than 6 months at least, and the course of the disease is fluctuating or continuously progressive, if proper treatment is not carried out, part of patients can progress to cirrhosis, and further progress to decompensated cirrhosis and various end-stage liver disease complications. As a common disease, the liver disease seriously harms the health of people in China for many years and greatly affects the life quality of people. At present, the clinical treatment of hepatitis A, hepatitis B and hepatitis C generally adopts a western medicine method, but the western medicine method usually treats the symptoms and root causes, cannot fundamentally condition human viscera, and achieves the aim of fundamentally treating the hepatitis A, the hepatitis B and the hepatitis C. Moreover, the traditional Chinese medicine has higher cost, longer treatment course and great side effect, and brings huge suffering to a plurality of patients with liver diseases. Chronic hepatitis and early cirrhosis belong to the categories of symptoms of hypochondriac pain, jaundice, accumulation and the like in traditional Chinese medicine, and the pathological changes of the chronic hepatitis and the early cirrhosis are liver loss and diarrhea and liver and spleen diseases caused by emotional, food and toxin and other reasons. The traditional Chinese medicine distinguishes 5 basic symptoms of liver depression and spleen deficiency, damp-heat middle-jiao stagnation, blood stasis and collaterals obstruction, liver and kidney yin deficiency and spleen and kidney yang deficiency, and clinically, patients with liver depression and spleen deficiency, damp-heat middle-jiao stagnation and blood stasis and collaterals obstruction are more. Because the current traditional Chinese medicine syndrome evolution law of the liver disease is not well known, the current traditional Chinese medicine preparation for treating the liver disease still has the defects of weak curative effect, slow effect and the like.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a novel traditional Chinese medicine composition for treating liver diseases, which has good curative effect on the liver diseases and low toxic and side effects. The traditional Chinese medicine composition contains the lalang grass rhizome, the hydrangea needle, the slender acanthopanax root and the lespedeza, has a unique formula and popular materials, can effectively reduce the cost, shorten the treatment course, has definite curative effect, and effectively meets the urgent need of the medicine for treating the liver disease patients.
The specific technical scheme of the invention is as follows:
a Chinese medicinal composition for treating hepatopathy comprises lalang grass rhizome, herba Damnacanthi, Acanthopanax gracilistylus W.W.W.W. Chen, and caulis Seu folium Lespedezae Bicoloris.
The traditional Chinese medicine composition preferably comprises the following components in parts by weight:
Figure GDA0003033242900000011
more preferably the following parts by weight:
Figure GDA0003033242900000021
the invention also aims to provide a medicament for treating liver diseases, which is prepared by crushing the traditional Chinese medicine composition or extracting the traditional Chinese medicine composition by using an aqueous solution, and directly or together with any one or more pharmaceutically acceptable auxiliary materials into a medicinal preparation. The pharmaceutical preparation is an oral preparation. Preferably, the oral preparation is decoction, tablet, capsule, pill or powder.
The method for extracting the traditional Chinese medicine composition by using the aqueous solution can be used for decocting the five medicinal materials by adding a proper amount of water for 3 times, for example, 10 times of water is added for 3 hours for the first time, 8 times of water is added for 2 hours for the second time, 6 times of water is added for 2 hours for the third time, and the decoction is combined and filtered to obtain the filtrate. The filtrate can be further processed into corresponding oral preparations.
The invention also aims to provide application of the traditional Chinese medicine composition in preparing a medicine for treating liver diseases. The liver disease is selected from acute and chronic hepatitis B, hepatitis A, hepatitis C, liver cirrhosis, hepatic ascites or alcoholic liver disease.
The invention combines the etiology, pathogenesis and pathological basis of liver diseases, starts from damp-heat toxin, qi stagnation and blood stasis, liver depression and spleen deficiency, takes heat clearing and detoxifying, meridian dredging and blood activating, dampness clearing and diuresis as the treatment basis, selects the combination of the cogongrass rhizome, the hydrangea needle, the slender acanthopanax, and the lespedeza, has the effects of clearing heat and detoxifying, inducing diuresis and reducing edema, meridian dredging and blood activating, and expelling wind-damp and tonifying liver and kidney, and is mainly used for treating various hepatitis, cirrhosis, liver ascites and the like.
Detailed Description
The present invention will be described in further detail with reference to examples, but it should be understood that the scope of the present invention is not limited to these examples.
EXAMPLE 1 preparation of the drug for treating liver diseases according to the present invention
The following components in parts by weight: 5-200 parts of cogongrass rhizome, 5-200 parts of hydrangea aspera, 10-100 parts of acanthopanax gracilistylus and 10-100 parts of lespedeza, drying and crushing to prepare powder, or decocting to prepare decoction, or adding a proper amount of water to decoct for 3 times, combining the decoctions, and filtering to obtain filtrate. The filtrate may be concentrated for further processing into a suitable formulation.
Specific examples are as follows:
1. chewable tablet
Figure GDA0003033242900000022
Decocting the above four materials with appropriate amount of water for 3 times, decocting with 10 times of water for 3 hr for the first time, decocting with 8 times of water for 2 hr for the second time, decocting with 6 times of water for 2 hr for the third time, mixing decoctions, and filtering to obtain filtrate. Or concentrating the filtrate, vacuum drying, pulverizing, sieving, adding lactose, dextrin, PEG6000, and pineapple essence, mixing, selecting appropriate punch die, and tabletting by direct powder tabletting method to obtain 1000 tablets. The dosage is as follows: 3 times daily, 3 tablets each time.
2. Sugar-coated tablet
Figure GDA0003033242900000031
Decocting the above four materials with appropriate amount of water for 3 times, decocting with 10 times of water for 3 hr for the first time, decocting with 8 times of water for 2 hr for the second time, decocting with 6 times of water for 2 hr for the third time, mixing decoctions, and filtering to obtain filtrate. Or concentrating the filtrate, vacuum drying, pulverizing, sieving, granulating with 80% ethanol, drying, adding magnesium stearate, tabletting, and sugar coating to obtain 1000 tablets. The dosage is as follows: 3 times daily, 3 tablets each time.
3. Film-coated tablet
Figure GDA0003033242900000032
Decocting the above four materials with appropriate amount of water for 3 times, decocting with 10 times of water for 3 hr for the first time, decocting with 8 times of water for 2 hr for the second time, decocting with 6 times of water for 2 hr for the third time, mixing decoctions, and filtering to obtain filtrate. Or concentrating the filtrate, vacuum drying, pulverizing, sieving, granulating with 80% ethanol, drying, adding magnesium stearate, tabletting, and coating to obtain 1000 tablets. The dosage is as follows: 3 times daily, 3 tablets each time.
4. Decoction preparation
Figure GDA0003033242900000033
The four raw materials are decocted into decoction according to the conventional method, the decoction is 100 doses, and one dose is taken in the morning, the middle and the evening respectively.
5. Powder preparation
Figure GDA0003033242900000041
The four raw materials are prepared into powder by the conventional method, and 1000 bags are prepared to obtain the Chinese medicinal composition. Three times daily, one bag each time.
6. Pill preparation
Figure GDA0003033242900000042
The four raw materials are prepared into pills according to the conventional method, and the pills are prepared into 1000 bags. Three times daily, one bag each time.
Example 2 pharmacological Activity examination of the pharmaceutical composition of the present invention on an animal model of acute liver injury
1. Experimental materials and experimental animals: the traditional Chinese medicine composition comprises a water extract of a traditional Chinese medicine composition, and an enzyme linked immunosorbent assay kit (OCT) containing canavalin A, alanine-glutamate Aminotransferase (ALT), superoxide dismutase (SOD), interleukin 1-ELISA (IL-1), tumor necrosis factor alpha (TNF-alpha) and ornithine carbamyl transferase; c57 mice.
2. Preparation of a sample:
preparation of a sample of the Chinese medicinal composition of the invention (group G): taking 15g of lalang grass rhizome, 15g of embroidery needle, 10g of acanthopanax gracilistylus and 8g of lespedeza, adding a proper amount of water, decocting, filtering, and concentrating the filtrate to a certain volume to obtain the traditional Chinese medicine.
Preparation of a traditional Chinese medicine composition (group C1) lacking cogongrass rhizome: taking 15g of embroidery needle, 10g of acanthopanax gracilistylus and 8g of lespedeza bicolor, adding a proper amount of water, decocting, filtering, and concentrating the filtrate to the same volume of the traditional Chinese medicine composition to obtain the traditional Chinese medicine composition.
Preparation of Chinese medicinal composition for lack of embroidery needle (group C2): taking 15g of cogongrass rhizome, 10g of acanthopanax gracilistylus and 8g of lespedeza, adding a proper amount of water, decocting, filtering, and concentrating the filtrate to the same volume of the traditional Chinese medicine composition to obtain the traditional Chinese medicine composition.
Preparation of acanthopanax sessiliflorus-lacking traditional Chinese medicine composition (group C3): taking 15g of lalang grass rhizome, 15g of embroidery needle and 8g of lespedeza bicolor, adding a proper amount of water, decocting, filtering, and concentrating the filtrate to the same volume of the traditional Chinese medicine composition to obtain the traditional Chinese medicine composition.
Preparation of lespedeza composition (group C4): taking 15g of lalang grass rhizome, 15g of embroidery needle and 10g of acanthopanax gracilistylus respectively, adding a proper amount of water for decocting, filtering, and concentrating the filtrate until the volume of the traditional Chinese medicine composition is the same.
Preparing single medicine samples: respectively taking 15g of lalang grass rhizome, 15g of embroidery needle, 10g of acanthopanax gracilistylus and 8g of lespedeza bicolor, decocting respectively, filtering, and concentrating the filtrate to the same volume as the traditional Chinese medicine composition to obtain single medicine samples: cogongrass rhizome (group S1), hydrangea needle (group S2), acanthopanax gracilistylus (group S3) and lespedeza (group S4).
3. Experimental dose: the Chinese medicinal composition extract (group G) is administered according to the dose of raw medicinal materials with mouse weight of 15mg/kg, and the Chinese medicinal composition extract and each single medicinal extract are converted according to the content of raw medicinal materials with the same amount in the Chinese medicinal composition.
4. The experimental method comprises the following steps: immune liver injury model method induced by sword bean protein
C57 mice 88 were randomly assigned to 11 groups: blank group, model group, traditional Chinese medicine composition group, rhizoma imperatae lacking composition group, hydrangea macrophylla lacking composition group, acanthopanax gracilistylus lacking composition group, lespedeza pedeza lacking composition group and each single medicine. The administration was performed by gavage 1 time a day, and equal volume of 1% sodium carboxymethylcellulose was administered to both blank group and model group for 2 weeks. After fasting for 2 hours on day 14, canavalin A was injected into the tail vein, and normal saline such as 25mg/kg was injected into the blank group. After 8 hours, anesthesia was performed with 10% chloral hydrate, blood was taken from the eyeball, and serum was separated to determine ALT value. Washing another liver tissue with normal saline, sucking, weighing, cutting into pieces, making into liver homogenate with mass fraction of 10%, centrifuging, collecting supernatant, and measuring values of SOD, OCT, TNF-alpha and IL-1.
5. The experimental results are as follows:
the serum ALT value and the OCT, TNF-alpha and IL-1 value in liver tissue of the model group mice are obviously increased, and the SOD value is obviously reduced. Compared with the model group, the samples have the effects of inhibiting the elevation of ALT level in the serum of the immune liver injury mouse, reducing the levels of OCT, TNF-alpha and IL-1 in liver tissues and increasing the SOD value to different degrees, and the results are shown in the table 1.
TABLE 1 Effect of Chinese medicinal composition with lack of taste on ALT, OCT, TNF-alpha, IL-1 and SOD value of immunological liver injury (x + -s, n ═ 8)
Group of ALT(U/L) OCT(U/L) TNF-α(pg/ml) IL-1(pg/ml) SOD(U/L)
Blank group 26.70±3.44 38.02±4.17 55.65±6.37 90.30±9.93 110.21±10.51
Model set 87.63±7.18 113.95±12.08 152.98±11.82 210.33±17.24 70.54±8.04
Group G 36.75±4.49* 49.80±5.05* 90.39±10.16* 132.48±10.71* 101.66±9.75*
Group C1 67.09±7.16 81.04±9.15 119.89±12.35 173.89±16.66 86.65±9.02
Group C2 70.84±8.30 72.65±8.02 106.67±11.46 168.21±17.45 80.89±8.77
Group C3 59.99±5.73 89.53±9.16 131.80±14.58 154.80±16.98 91.53±10.06
Group C4 64.38±6.89 78.56±8.68 124.83±13.79 173.84±19.05 88.47±9.72
S1 group 71.49±8.20 69.99±6.84 105.96±11.33 180.32±18.95 79.99±8.16
S2 group 62.96±5.97 70.55±7.54 118.88±12.06 178.64±19.17 82.32±9.05
S3 group 68.48±7.05 81.77±8.41 127.34±13.20 169.94±17.86 89.10±9.56
S4 group 70.92±7.66 76.30±7.69 130.46±13.92 181.63±19.30 84.27±9.38
The results show that the protective effect of any one traditional Chinese medicine composition and a single component on the immunological liver injury is not greatly different, the synergistic effect is not obvious, but how to combine and improve the curative effect in the prior art is not regular and can be recycled. However, the four-medicine composition has the strongest protective effect on immunological liver injury, and shows good synergistic treatment effect.
EXAMPLE 2 clinical pharmacodynamic Studies of the pharmaceutical compositions of the present invention
The pharmaceutical composition (decoction in example 1) and a control sample hepatitis B (Jinan Sanzhu Fuer pharmaceutical) are used for 102 chronic hepatitis B patients in total, and are randomly divided into 57 samples of the sample group and 45 samples of the hepatitis B drug, wherein 59 male patients and 43 female patients are 75 years old and 14 years old at the maximum and are taken one dose every day after 1 month of three-time taking, and the results of liver function index, physical strength, hepatic region somatosensory, jaundice, anorexia and the like are rechecked, and the results are statistically analyzed. The effective rates of the sample of the invention on the symptoms of liver function recurrence, hypodynamia, liver discomfort, jaundice and anorexia are respectively 91.8%, 72.3%, 84.6%, 90.3% and 92.7%. The effective rates of the control samples on the symptoms of liver function recurrence, asthenia, liver discomfort, jaundice and anorexia are 71.0%, 68.3%, 60.6%, 80.4% and 72.9%, respectively. The results of the two groups are obviously different and have statistical significance.

Claims (5)

1. A traditional Chinese medicine composition for treating liver diseases is characterized by comprising the following traditional Chinese medicines in parts by weight:
150 parts of cogongrass rhizome
Embroidery needle 150 parts
Acanthopanax gracilistylus 100 parts
80 parts of lespedeza bicolor.
2. A medicine for treating liver diseases, which is characterized in that the traditional Chinese medicine composition of claim 1 is prepared into a pharmaceutical preparation directly or together with any one or more pharmaceutically acceptable auxiliary materials after being crushed or extracted.
3. The medicament of claim 2, wherein said pharmaceutical formulation is an oral formulation.
4. The medicament according to claim 3, wherein the oral preparation is decoction, tablet, capsule, pill or powder.
5. Use of the Chinese medicinal composition of claim 1 in the preparation of a medicament for the treatment of liver disease.
CN201811327689.3A 2018-11-08 2018-11-08 A Chinese medicinal composition for treating hepatopathy Active CN109172756B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811327689.3A CN109172756B (en) 2018-11-08 2018-11-08 A Chinese medicinal composition for treating hepatopathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811327689.3A CN109172756B (en) 2018-11-08 2018-11-08 A Chinese medicinal composition for treating hepatopathy

Publications (2)

Publication Number Publication Date
CN109172756A CN109172756A (en) 2019-01-11
CN109172756B true CN109172756B (en) 2021-07-16

Family

ID=64938612

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811327689.3A Active CN109172756B (en) 2018-11-08 2018-11-08 A Chinese medicinal composition for treating hepatopathy

Country Status (1)

Country Link
CN (1) CN109172756B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1943387A (en) * 2006-08-21 2007-04-11 李浪辉 Cool tea
CN102836348A (en) * 2011-06-20 2012-12-26 江西中医学院 Novel traditional Chinese medicine formula for treatment of hepatopathy
CN104324160A (en) * 2014-10-29 2015-02-04 施秀丽 Medicinal liquor for treating rheumatism and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1943387A (en) * 2006-08-21 2007-04-11 李浪辉 Cool tea
CN102836348A (en) * 2011-06-20 2012-12-26 江西中医学院 Novel traditional Chinese medicine formula for treatment of hepatopathy
CN104324160A (en) * 2014-10-29 2015-02-04 施秀丽 Medicinal liquor for treating rheumatism and preparation method thereof

Also Published As

Publication number Publication date
CN109172756A (en) 2019-01-11

Similar Documents

Publication Publication Date Title
CN103285231B (en) Medicine composition for diabetes adjunctive therapy and preparation method thereof
CN102078473B (en) Traditional Chinese medicine preparation for treating chronic hepatitis b and preparation method thereof
CN104435749B (en) A kind of dendrobium candidum compound preparation and its preparation method and application
CN110787233B (en) Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof
CN103520572A (en) Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition
CN113209166A (en) Anti-aging traditional Chinese medicine composition containing nicotinamide mononucleotide and preparation method thereof
CN101342249B (en) Chinese medicine formulations for treating hepatitis B and preparation method thereof
CN118434431A (en) Traditional Chinese medicine composition and preparation method and application thereof
CN109172756B (en) A Chinese medicinal composition for treating hepatopathy
CN107029173B (en) Pharmaceutical composition for treating primary liver cancer
CN102526444A (en) Traditional Chinese medicine composition for invigorating kidney and strengthening yang and preparation method thereof
CN104042895A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof
CN110755601B (en) Kidney bean lectin plant medicine composition for treating HIV/AIDS immune reconstruction defect and preparation method and application thereof
CN103768579A (en) Traditional Chinese medicine for reducing blood sugar and preparation method thereof
US11957726B2 (en) Pharmaceutical composition for controlling blood sugar
CN105596890A (en) Method for preparing traditional Chinese medicine composition for treating lung cancer
CN104337898B (en) A kind of Chinese medicine composition of the treatment gout containing Semen Pruni
CN115252729B (en) Traditional Chinese medicine composition for treating diabetes and application thereof
CN114796417B (en) Blood sugar reducing traditional Chinese medicine formula and preparation method thereof
CN109394968B (en) Composition with auxiliary blood sugar reducing function and application thereof
CN106729577B (en) Traditional Chinese medicine composition for treating rheumatism and preparation method thereof
CN105943860A (en) Medicine preparation for treating diabetes mellitus and preparation method thereof
CN107213323B (en) Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof
CN104758749A (en) Traditional Chinese medicine composition for treating liver cancer
CN118453693A (en) Use of two-component formula for preventing and treating non-alcoholic steatohepatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant